Plain-English translation of NCT07932691 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Ulcerative Colitis (UC) research guide →Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is an early-stage study testing a new medication called VDJ010, which is injected under the skin. The trial will first give healthy volunteers a single injection to make sure it's safe, then give patients with moderate-to-severe ulcerative colitis multiple injections over several weeks. The medication is designed to help calm the immune system and reduce bowel inflammation.
Ulcerative colitis causes painful inflammation and bleeding in the colon, and some patients don't respond well to existing treatments. This medication takes a different approach by boosting a specific type of immune cell that helps calm inflammation, which researchers hope could offer patients a new option.
You likely qualify if…
You likely don't qualify if…
If you're a healthy volunteer, you'll receive one injection and then return for blood tests and check-ups over the next 6 weeks. If you have ulcerative colitis, you'll receive three injections given under the skin every two weeks, plus blood work and colonoscopy visits, with follow-up visits lasting about 8 weeks total. You'll also have blood drawn to check how your immune system is responding and whether the treatment is reducing your bowel inflammation.
AI-generated summary from trial data · Nov 15, 2026 · Not medical advice
China